Ivosidenib extends overall survival in patients with previously treated, advanced cholangiocarcinoma whose disease harbors IDH1 mutations. Median overall survival was 10.3 months in patients who received the drug, versus 7.5 months in the placebo group. The difference was even larger—5.1 months—when researchers accounted for patient crossover into the treatment group.

You do not currently have access to this content.